Reappraisal of the clinical effect of mepolizumab

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e20
Journal	The Lancet Respiratory Medicine
Volume	5
Issue number	6
DOIs	https://doi.org/10.1016/S2213-2600(17)30183-2
Publication status	Published - Jun 2017

Keywords

@article{818139f4930a485786ac609151dfe561,

title = "Reappraisal of the clinical effect of mepolizumab",

keywords = "Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma, Eosinophils, Humans",

author = "Lipworth, \{Brian J\} and Sunny Jabbal",

year = "2017",

month = jun,

doi = "10.1016/S2213-2600(17)30183-2",

language = "English",

volume = "5",

pages = "e20",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Reappraisal of the clinical effect of mepolizumab

AU - Lipworth, Brian J

AU - Jabbal, Sunny

PY - 2017/6

Y1 - 2017/6

KW - Anti-Asthmatic Agents

KW - Antibodies, Monoclonal, Humanized

KW - Asthma

KW - Eosinophils

KW - Humans

U2 - 10.1016/S2213-2600(17)30183-2

DO - 10.1016/S2213-2600(17)30183-2

M3 - Letter

C2 - 28664852

SN - 2213-2600

VL - 5

SP - e20

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 6

ER -